SCHEMBL5282257

SCHEMBL5282257

NC(=O)N1C=CC2=C(CC(=O)C=C2)c2ccccc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.40
MAPT P10636 2/20 0.40
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
CYP3A4 P08684 1/20 0.40
PABPC1 P11940 1/20 0.40
BLM P54132 1/20 0.40
KMT2A Q03164 1/20 0.40
LMNA P02545 1/20 0.34
TSHR P16473 1/20 0.34
MAPK1 P28482 1/20 0.34
SCN4A P35499 1/20 0.34
SCN5A Q14524 1/20 0.34
SCN9A Q15858 1/20 0.34
NOTUM Q6P988 1/20 0.32
CES1 P23141 2/20 0.31
NPC1 O15118 1/20 0.31
BCHE P06276 2/20 0.31
HSP90AA1 P07900 1/20 0.31
PKM P14618 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5969695 0.77 KDM4E (0.32) ALDH1A1MAPTKDM4EMEN1CYP3A4
SCHEMBL3765842 0.71 LMNA (0.49) ALDH1A1MAPTKDM4EMEN1CYP3A4
SCHEMBL3015876 0.64 MAOA (0.37) ALDH1A1KDM4EKMT2ACES1BCHE
SCHEMBL7329883 0.63 MAPT (0.41) ALDH1A1MAPTKDM4EMEN1CYP3A4
SCHEMBL10977545 0.63 KDM4E (0.33) ALDH1A1KDM4EMEN1KMT2AACHE
SCHEMBL212380 0.60 LMNA (0.38) ALDH1A1MAPTKDM4EMEN1CYP3A4
SCHEMBL3266678 0.60 MEN1 (0.41) ALDH1A1MAPTKDM4EMEN1CYP3A4
SCHEMBL3691734 0.60 LMNA (0.55) LMNATSHRMAPK1SCN4ASCN5A
SCHEMBL9435710 0.59 GSK3A (0.42) ALDH1A1MAPTKDM4EMEN1BLM
SCHEMBL31495947 0.59 GSK3A (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070264358-A1 Methods and Compositions for Treating Mood Disorder MOOD MANAGEMENT SCIENCES, INC. 2007-11-15 US disclosed
WO-2007007182-A2 SOLID AND LIQUID DOSAGE FORMS OF AN ANTIEPILEPTIC AGENT AUROBINDO PHARMA LIMITED (IN) 2007-01-18 WO disclosed
EP-1729737-A1 DISINTEGRATING TABLETS COMPRISING LICARBAZEPINE Novartis AG (CH) 2006-12-13 EP disclosed
US-20060111343-A1 Oxcarbazepine dosage forms GLENMARK PHARMACEUTICALS LIMITED (IN) 2006-05-25 US disclosed
WO-2005092290-A1 DISINTEGRATING TABLETS COMPRISING LICARBAZEPINE NOVARTIS AG (CH) 2005-10-06 WO disclosed
EP-1528927-A1 USE OF CARBOXAMIDES FOR THE TREATMENT OF TINNITUS Novartis AG (CH) 2005-05-11 EP disclosed
EP-1513816-A2 METHOD OF PREPARING A 5H-DIBENZ(B,F)AZEPINE-5-CARBOXAMIDE TARO PHARMACEUTICALS U.S.A., INC. (US) 2005-03-16 EP disclosed
WO-2004014391-A1 USE OF CARBOXAMIDES FOR THE TREATMENT OF TINNITUS NOVARTIS AG (CH) 2004-02-19 WO disclosed
WO-2003106414-A2 METHOD OF PREPARING A 5H-DIBENZ[B,F]AZEPINE-5-CARBOXAMIDE TARO PHARMACEUTICALS U.S.A., INC. (US) 2003-12-24 WO disclosed
US-4559174-A NITRATION, REDUCTION AND HYDROLYSIS OF 5-CYANO5H-DIBENZ/B,FLAZEPINE CIBA GEIGY CORPORATION (US) 1985-12-17 US disclosed
US-4452738-A Process for the manufacture of 5-carbamoyl-10-oxo-10,11-dihydro-5H-dibenz[b,]azepine CIBA-GEIGY CORPORATION (US) 1984-06-05 US disclosed